Convergence Partners的动态

?? News out of Spain on a €5.5 million funding round for Huntington’s treatment | SOM Biotech closes internal round to support the completion of a Phase IIb study. ? What to know: ? Huntington’s is a genetic neurodegenerative disorder with an incidence of 0.48 per 100,000 persons, with a higher incidence in Europe and North America than Asia. ? SOM #Biotech operates on a unique, proprietary #AI platform known as SOMAIPRO, and it is dedicated to identifying new mechanisms of action of small molecule drugs for diseases with a focus on orphan disorders in the CNS. ? The lead candidate is SOM3355 which aims to treat the involuntary movements associated with Huntington's disease. ? Preliminary data from the Phase IIb clinical study is expected in Q3 of 2024. ? Link to full press release: https://lnkd.in/ewcBXaPg Key People to Follow from SOM biotech: ? Silvia Panigone, Executive Chair ? Catherine Scart-Gres, Chief Medical Officer #Research #Healthcare #VentureCapital #BrainHealth